Conduit Pharmaceuticals- Warrants (22/09/2028) Long Term Debt

The latest long-term debt for CDTTW is $1.3B as of June 2026. That compares with $1.4B in the prior-year period — down 3.6% year over year. Investors often review this figure alongside Conduit Pharmaceuticals- Warrants (22/09/2028)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, CDTTW's long-term debt moved from $1.4B to $1.3B — a 3.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Conduit Pharmaceuticals- Warrants (22/09/2028)'s operating scale or balance-sheet position.

A long-term debt figure of $1.3B for CDTTW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CDTTW's long-term debt ($1.3B), review year-over-year change from $1.4B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.